Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4211710
Max Phase: Preclinical
Molecular Formula: C29H31N5O3
Molecular Weight: 497.60
Molecule Type: Small molecule
Associated Items:
ID: ALA4211710
Max Phase: Preclinical
Molecular Formula: C29H31N5O3
Molecular Weight: 497.60
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: Nc1ncnc2c1c(-c1ccc(Oc3ccccc3)cc1)cn2[C@H]1CC[C@H](N2CCC[C@@H]2C(=O)O)CC1
Standard InChI: InChI=1S/C29H31N5O3/c30-27-26-24(19-8-14-23(15-9-19)37-22-5-2-1-3-6-22)17-34(28(26)32-18-31-27)21-12-10-20(11-13-21)33-16-4-7-25(33)29(35)36/h1-3,5-6,8-9,14-15,17-18,20-21,25H,4,7,10-13,16H2,(H,35,36)(H2,30,31,32)/t20-,21-,25-/m1/s1
Standard InChI Key: DORRCVAXQFZOLU-DNRQZRRGSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 497.60 | Molecular Weight (Monoisotopic): 497.2427 | AlogP: 5.51 | #Rotatable Bonds: 6 |
Polar Surface Area: 106.50 | Molecular Species: ZWITTERION | HBA: 7 | HBD: 2 |
#RO5 Violations: 1 | HBA (Lipinski): 8 | HBD (Lipinski): 3 | #RO5 Violations (Lipinski): 1 |
CX Acidic pKa: 0.89 | CX Basic pKa: 11.08 | CX LogP: 2.13 | CX LogD: 1.94 |
Aromatic Rings: 4 | Heavy Atoms: 37 | QED Weighted: 0.36 | Np Likeness Score: -0.35 |
1. Koda Y, Kikuzato K, Mikuni J, Tanaka A, Yuki H, Honma T, Tomabechi Y, Kukimoto-Niino M, Shirouzu M, Shirai F, Koyama H.. (2017) Identification of pyrrolo[2,3-d]pyrimidines as potent HCK and FLT3-ITD dual inhibitors., 27 (22): [PMID:29037944] [10.1016/j.bmcl.2017.10.012] |
Source(1):